World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
49330
World Ranking
12904
National Ranking
6596

Neal D. Shore publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Neal D. Shore sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,179 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Neal D. Shore D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Neal D. Shore sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Neal D. Shore is affiliated with the Carolina Urologic Research Center in the United States. Their research primarily contributes to the field of Medicine, with a focus on specialties including Pulmonary and Respiratory Medicine, Oncology, Surgery, Radiology, Nuclear Medicine and Imaging, and Cancer Research.

The main topics covered in their body of work involve Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment, Bladder and Urothelial Cancer Treatments, Cancer, Lipids, and Metabolism, PARP inhibition in cancer therapy, and Hormonal and reproductive studies.

Neal D. Shore has co-authored frequently with the following researchers:

  • Fred Saad
  • Karim Fizazi
  • Ugo De Giorgi
  • Arun Azad
  • Bertrand Tombal

They have published multiple papers in prominent venues, including:

  • Journal of Clinical Oncology
  • The Journal of Urology
  • Annals of Oncology
  • Future Oncology
  • European Urology

Recent notable publications with corresponding years and venues are:

  • Olaparib for Metastatic Castration-Resistant Prostate Cancer (2020) in New England Journal of Medicine
  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer (2020) in New England Journal of Medicine
  • Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial (2023) in The Lancet
  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer (2020) in New England Journal of Medicine
  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer (2020) in New England Journal of Medicine

Their scientific output reflects extensive work on prostate cancer therapies, with investigations into hormonal treatments, androgen-deprivation therapies, and targeted PARP inhibitor therapies.

Best Publications

  • Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

    Philip W. Kantoff;Celestia S. Higano;Neal D. Shore;E. Roy Berger

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

    Karim Fizazi;Michael Carducci;Matthew Smith;Ronaldo Damião

  • Olaparib for metastatic castration-resistant prostate cancer

    Johann de Bono;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer

    Maha Hussain;Karim Fizazi;Fred Saad;Per Rathenborg

  • Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial.

    Matthew R Smith;Fred Saad;Robert Coleman;Neal Shore

  • ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

    Andrew J. Armstrong;Russell Z. Szmulewitz;Daniel P. Petrylak;Jeffrey Holzbeierlein

  • Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

    F. Saad;J. E. Brown;C. Van Poznak;T. Ibrahim

  • Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

    Karim Fizazi;Neal Shore;Teuvo L. Tammela;Albertas Ulys

  • The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

    Laurence Klotz;Laurent Boccon-Gibod;Neal D. Shore;Cal Andreou

  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

    Maha Hussain;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer

    Dipen J. Parekh;Sanoj Punnen;Daniel D. Sjoberg;Scott W. Asroff

  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

    S Gillessen;A Omlin;G Attard;J S de Bono

  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

    Neal D. Shore;Fred Saad;Michael S. Cookson;Daniel J. George

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

    Silke Gillessen;Gerhardt Attard;Tomasz M. Beer;Himisha Beltran

  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

    Cora N. Sternberg;Karim Fizazi;Fred Saad;Neal D. Shore

  • Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)

    Dana E. Rathkopf;Matthew R. Smith;Johann S. De Bono;Christopher J. Logothetis

  • Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

    Neal D Shore;Simon Chowdhury;Arnauld Villers;Laurence Klotz

Frequent Co-Authors

Karim Fizazi
Karim Fizazi University of Paris-Saclay
Fred Saad
Fred Saad University of Montreal
Matthew R. Smith
Matthew R. Smith Harvard University
E. David Crawford
E. David Crawford University of California, San Diego
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Celestia S. Higano
Celestia S. Higano University of Washington
Oliver Sartor
Oliver Sartor Tulane University
Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
Emmanuel S. Antonarakis
Emmanuel S. Antonarakis University of Minnesota

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean becoming a physician. The U.S. offers a range of flexible online degrees and alternative pathways for students with different interests and backgrounds. These programs are ideal for career changers, working professionals, or those looking for a direct pathway into healthcare fields.

For instance, if you are interested in becoming a nurse but want to avoid lengthy, traditional admissions tests, consider a nursing school that does not require teas test. This option streamlines the admissions process, making nursing more accessible for many students.

If speed is important, look into accelerated healthcare programs that fast-track you into health administration or management roles. Nurses seeking career advancement can pursue an rn to np bridge program, allowing licensed RNs to become nurse practitioners with greater responsibility.

For those interested in preventive health or public education, there’s the option of a comprehensive nutrition bachelor degree online. This program provides a foundation for careers in wellness, dietetics, or community health.

These online degrees and career pathways offer alternative routes into healthcare—helping you find the best fit for your skills and passions within the field of medicine.

Best Scientists Citing Neal D. Shore

Trending Scientists

Recently Published Articles